NCT01051232 - A Study To Investigate Safety And Pharmacokinetics Of A Single Dose Of PF-00868554 (Filibuvir) In Japanese Healthy Adult Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions

Healthy

Interventions

DRUG

Active

Six subjects will receive PF-00868554 (filibuvir) 100 mg under fasting condition.

DRUG

Placebo

Two subjects will receive the placebo under fasting condition.

DRUG

Active

Six subjects will receive PF-00868554 (filibuvir) 300 mg under fasting condition.

DRUG

Placebo

Two subjects will receive the placebo under fasting condition.

DRUG

Active

Six subjects will receive PF-00868554 (filibuvir) 500 mg under fasting condition.

DRUG

Placebo

Two subjects will receive the placebo under fasting condition.

Trial Locations (1)

Pfizer Investigational Site, Shinjuku-ku